Keebeck Wealth Management Acquires New Position in Thermo Fisher Scientific Inc. $TMO

Keebeck Wealth Management acquired a new stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 799 shares of the medical research company’s stock, valued at approximately $401,000.

A number of other institutional investors have also made changes to their positions in TMO. Legacy Wealth Managment LLC ID boosted its holdings in shares of Thermo Fisher Scientific by 78.6% in the 1st quarter. Legacy Wealth Managment LLC ID now owns 50 shares of the medical research company’s stock valued at $25,000 after buying an additional 22 shares during the period. Kilter Group LLC bought a new position in Thermo Fisher Scientific in the second quarter worth about $25,000. Allied Private Wealth LLC acquired a new position in Thermo Fisher Scientific in the second quarter valued at approximately $26,000. High Note Wealth LLC grew its holdings in shares of Thermo Fisher Scientific by 170.6% during the fourth quarter. High Note Wealth LLC now owns 46 shares of the medical research company’s stock valued at $27,000 after purchasing an additional 29 shares during the last quarter. Finally, Swiss RE Ltd. acquired a new stake in shares of Thermo Fisher Scientific during the 4th quarter worth approximately $28,000. 89.23% of the stock is currently owned by institutional investors.

Thermo Fisher Scientific Stock Up 0.2%

NYSE TMO opened at $629.02 on Friday. Thermo Fisher Scientific Inc. has a 12 month low of $435.27 and a 12 month high of $643.99. The company has a market capitalization of $232.58 billion, a P/E ratio of 33.84, a PEG ratio of 2.56 and a beta of 0.85. The company’s 50 day simple moving average is $542.53 and its 200 day simple moving average is $509.70. The company has a debt-to-equity ratio of 0.74, a current ratio of 1.55 and a quick ratio of 1.18.

Thermo Fisher Scientific (NYSE:TMO) last issued its earnings results on Thursday, July 23rd. The medical research company reported $6.03 earnings per share for the quarter, topping analysts’ consensus estimates of $5.71 by $0.32. The firm had revenue of $11.99 billion during the quarter, compared to analysts’ expectations of $11.71 billion. Thermo Fisher Scientific had a net margin of 15.04% and a return on equity of 17.09%. The firm’s revenue for the quarter was up 10.5% compared to the same quarter last year. During the same period last year, the firm posted $4.28 earnings per share. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. Equities research analysts expect that Thermo Fisher Scientific Inc. will post 25.12 earnings per share for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Thursday, October 15th. Investors of record on Tuesday, September 15th will be issued a $0.47 dividend. This represents a $1.88 dividend on an annualized basis and a dividend yield of 0.3%. The ex-dividend date is Tuesday, September 15th. Thermo Fisher Scientific’s payout ratio is presently 10.11%.

Analysts Set New Price Targets

TMO has been the subject of a number of analyst reports. Morgan Stanley boosted their price objective on Thermo Fisher Scientific from $620.00 to $650.00 and gave the company an “overweight” rating in a research report on Friday, July 24th. Evercore set a $570.00 target price on Thermo Fisher Scientific in a research note on Monday, July 6th. Barclays boosted their price target on shares of Thermo Fisher Scientific from $625.00 to $650.00 and gave the company an “overweight” rating in a report on Friday, July 24th. Jefferies Financial Group reaffirmed a “buy” rating and issued a $630.00 price objective on shares of Thermo Fisher Scientific in a report on Thursday, July 23rd. Finally, Sanford C. Bernstein initiated coverage on shares of Thermo Fisher Scientific in a research note on Friday, June 26th. They set a “market perform” rating and a $520.00 target price for the company. One investment analyst has rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and six have given a Hold rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $619.41.

Insider Activity at Thermo Fisher Scientific

In other news, CAO Joseph R. Holmes sold 420 shares of the company’s stock in a transaction on Friday, August 7th. The stock was sold at an average price of $584.81, for a total transaction of $245,620.20. Following the completion of the sale, the chief accounting officer directly owned 2,966 shares of the company’s stock, valued at $1,734,546.46. This represents a 12.40% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CEO Marc N. Casper sold 4,608 shares of the stock in a transaction on Friday, August 7th. The shares were sold at an average price of $586.12, for a total value of $2,700,840.96. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 63,493 shares of company stock valued at $37,657,681 over the last ninety days. Company insiders own 0.33% of the company’s stock.

About Thermo Fisher Scientific

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.